Literature DB >> 22947420

Angiotensin converting enzyme 2 and atherosclerosis.

Yutang Wang1, Chris Tikellis, Merlin C Thomas, Jonathan Golledge.   

Abstract

Angiotensin converting enzyme 2 (ACE2) is a homolog of angiotensin converting enzyme (ACE) which generates angiotensin II from angiotensin I. ACE, its product angiotensin II and the downstream angiotensin type I receptor are important components of the renin-angiotensin system (RAS). Angiotensin II, the most important component of the RAS, promotes the development of atherosclerosis. The identification of ACE2 in 2000 opened a new chapter of research on the regulation of the RAS. ACE2 degrades pro-atherosclerotic angiotensin II and generates anti-atherosclerotic angiotensin 1-7. In this review, we explored the importance of ACE2 in protecting experimental animals from developing atherosclerosis and its involvement in human atherosclerosis. We also examined the published evidence assessing the importance of ACE2 in different cell types relevant to atherosclerosis and putative underlying cellular and molecular mechanisms linking ACE2 with protection from atherosclerosis. ACE2 shifts the balance from angiotensin II to angiotensin 1-7 inhibiting the progression of atherosclerosis in animal models.
Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22947420     DOI: 10.1016/j.atherosclerosis.2012.08.018

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  16 in total

1.  ACE2 and Ang-(1-7) protect endothelial cell function and prevent early atherosclerosis by inhibiting inflammatory response.

Authors:  Yue-Hui Zhang; Yong-huan Zhang; Xue-Fei Dong; Qing-Qing Hao; Xiao-Ming Zhou; Qing-Tao Yu; Shu-Ying Li; Xu Chen; Abdulai Fallah Tengbeh; Bo Dong; Yun Zhang
Journal:  Inflamm Res       Date:  2015-02-27       Impact factor: 4.575

Review 2.  Neuroprotective mechanisms of the ACE2-angiotensin-(1-7)-Mas axis in stroke.

Authors:  Douglas M Bennion; Emily Haltigan; Robert W Regenhardt; U Muscha Steckelings; Colin Sumners
Journal:  Curr Hypertens Rep       Date:  2015-02       Impact factor: 5.369

Review 3.  The roles of FGF21 in atherosclerosis pathogenesis.

Authors:  Farzane Shanebandpour Tabari; Ansar Karimian; Hadi Parsian; Vahid Rameshknia; Ata Mahmoodpour; Maryam Majidinia; Mahmood Maniati; Bahman Yousefi
Journal:  Rev Endocr Metab Disord       Date:  2019-03       Impact factor: 6.514

4.  Diminazene enhances stability of atherosclerotic plaques in ApoE-deficient mice.

Authors:  Rodrigo A Fraga-Silva; Fabrizio Montecucco; Fabiana P Costa-Fraga; Alessio Nencioni; Irene Caffa; Maiia E Bragina; François Mach; Mohan K Raizada; Robson A S Santos; Rafaela F da Silva; Nikolaos Stergiopulos
Journal:  Vascul Pharmacol       Date:  2015-08-22       Impact factor: 5.773

Review 5.  Heteromeric Solute Carriers: Function, Structure, Pathology and Pharmacology.

Authors:  Stephen J Fairweather; Nishank Shah; Stefan Brӧer
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

6.  Interactions among Candidate Genes Selected by Meta-Analyses Resulting in Higher Risk of Ischemic Stroke in a Chinese Population.

Authors:  Man Luo; Jiaoxing Li; Xunsha Sun; Rong Lai; Yufang Wang; Xiaowei Xu; Wenli Sheng
Journal:  PLoS One       Date:  2015-12-28       Impact factor: 3.240

7.  The ACE2-Ang (1-7)-Mas receptor axis attenuates cardiac remodeling and fibrosis in post-myocardial infarction.

Authors:  Juan Wang; Wen He; Liping Guo; Yin Zhang; Hui Li; Suxia Han; Difei Shen
Journal:  Mol Med Rep       Date:  2017-06-23       Impact factor: 2.952

8.  Functional and Biochemical Endothelial Profiling In Vivo in a Murine Model of Endothelial Dysfunction; Comparison of Effects of 1-Methylnicotinamide and Angiotensin-converting Enzyme Inhibitor.

Authors:  Anna Bar; Mariola Olkowicz; Urszula Tyrankiewicz; Edyta Kus; Krzysztof Jasinski; Ryszard T Smolenski; Tomasz Skorka; Stefan Chlopicki
Journal:  Front Pharmacol       Date:  2017-04-10       Impact factor: 5.810

9.  Cardiovascular disease as a biomarker for an increased risk of COVID-19 infection and related poor prognosis.

Authors:  Nicola Ielapi; Noemi Licastro; Michele Provenzano; Michele Andreucci; Stefano de Franciscis; Raffaele Serra
Journal:  Biomark Med       Date:  2020-05-19       Impact factor: 2.851

10.  Diminazene Aceturate Stabilizes Atherosclerotic Plaque and Attenuates Hepatic Steatosis in apoE-Knockout Mice by Influencing Macrophages Polarization and Taurine Biosynthesis.

Authors:  Aneta Stachowicz; Anna Wiśniewska; Katarzyna Kuś; Magdalena Białas; Magdalena Łomnicka; Justyna Totoń-Żurańska; Anna Kiepura; Kamila Stachyra; Maciej Suski; Beata Bujak-Giżycka; Jacek Jawień; Rafał Olszanecki
Journal:  Int J Mol Sci       Date:  2021-05-30       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.